Topic summary

[2026 update] Publication patterns in the BPC-157 literature, examined

Compounds › Repair & healing peptides BPC-157 observational data TB-500 Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 20, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

e.almeidaTL2Member2 Jan 2026#3

i.guerrero, post #1: Publication patterns in the BPC-157 literature, examined Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024). Please read it before posting; the discussion is much better when everyone has. The question I would like us to start with is what the trial set… Go to post

I read the opening post twice before replying, because I had assumed the opposite.

Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does not show safety profile in humans, and does not show whether the effect survives in a more complex biological system. That is not a criticism of preclinical work — it is what preclinical work is for.

21 likes in reply to #1 7mo

m.marchettiTL2 Moderator Solution2 Feb 2026#8

Picking up post #5: that is the part I would want checked first.

The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and the distinction matters, but it also means treatment plans based on these compounds are being built on theoretical grounds, not empirical ones.

12 likes 6mo

s.kuuselaTL2 Moderator12 Feb 2026#10

post #9 is right about the mechanism and I think understates the practical bit.

What would change the position on repair peptides: adequately powered, published, peer-reviewed randomised controlled human trials with pre-specified outcomes. That is the standard applied to every other therapeutic claim on this site and it is the standard applied here.

30 likes 5mo

n.nybergTL2 Moderator14 Mar 2026#16

BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.

26 likes 4mo

t.brandtTL2 Moderator1 Apr 2026#20

Why plausible mechanism is not evidence of effect: a mechanism that is chemically or biologically plausible can fail in practice for dozens of reasons — bioavailability, off-target effects, metabolism, clearance, or simply that the mechanism does not do what the theory predicts in a living system. Plausibility is necessary for hope but not sufficient for evidence.

19 likes 4mo

Read the full topic (20 posts)

This topic was referenced in

About the Repair & healing peptides categoryCompounds › Repair & healing peptides · 4 replies
What would change my mind about repair peptides: a specific answer — one year onCompounds › Repair & healing peptides · 13 replies
BPC-157: what the rodent literature actually shows, and what it does not — does this still hold?Compounds › Repair & healing peptides · 10 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Why the absence of controlled human data on BPC-157 matters more than people admit Compounds › Repair & healing peptides needs a source BPC-157 preprint Solved Why the absence of controlled human data on BPC-157 matters more than people admit — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing STEP 8 ( JAMA , 2022) with…	+60	66	16k	1d
TB-500 and thymosin beta-4: the fragment versus the protein Compounds › Repair & healing peptides observational data TB-500 BPC-157 preprint TB-500 and thymosin beta-4: the fragment versus the protein Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…	+107	118	22k	11mo
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Compounds › Repair & healing peptides TB-500 preprint observational data needs a source Solved On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019)…	+77	84	54k	11mo
Why plausible mechanism is not evidence of effect Compounds › Repair & healing peptides TB-500 preprint observational data Solved Closed Asking directly, because I could not find a straight answer: Why plausible mechanism is not evidence of effect Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the discussion is much…	+14	18	57k	13mo
BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? Compounds › Repair & healing peptides observational data needs a source BPC-157 TB-500 Solved The question in the title: BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen…	+6	10	3.1k	1d

Related topics — sharing the tags BPC-157, observational data, TB-500

Topic	Participants	Replies	Views	Activity
Whether an aggregate is worth publishing at all: a disputed topic — does this still hold? Data & Tools › Datasets data table confounding observational data Solved Whether an aggregate is worth publishing at all: a disputed topic — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to understand…	+14	18	3.4k	2mo
A structured critique template this community uses — a second dataset Evidence › Study critique observational data effect size confounding Solved On the subject in the title: A structured critique template this community uses — a second dataset Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it before…	+47	51	16k	15h
Immortal time bias in a claims-database study Evidence › Study critique risk of bias observational data disputed confounding Closed Immortal time bias in a claims-database study — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…	+29	34	28k	11mo
Reading a rodent study on a secretagogue without over-extrapolating Compounds › Secretagogues & GH axis observational data GHRP class CJC-1295 needs a source Closed Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of…	+50	54	32k	10mo
Evidence quality in the secretagogue literature: an honest assessment Compounds › Secretagogues & GH axis ipamorelin observational data GHRP class tesamorelin Solved Evidence quality in the secretagogue literature: an honest assessment Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with STEP…		2	25k	9d